Hypothalamic hormones and cancer

Andrew V Schally, A. M. Comaru-Schally, A. Nagy, M. Kovacs, K. Szepeshazi, A. Plonowski, J. L. Varga, G. Halmos

Research output: Contribution to journalArticle

248 Citations (Scopus)

Abstract

The use of peptide analogs for the therapy of various cancers is reviewed. Inhibition of the pituitary - gonadal axis forms the basis for oncological applications of luteinizing hormone-releasing hormone (LH-RH) agonists and antagonists, but direct effects on tumors may also play a role. Analogs of somatostatin are likewise used for treatment of various tumors. Radiolabeled somatostatin analogs have been successfully applied for the localization of tumors expressing somatostatin receptors. Studies on the role of tumoral LH-RH, growth hormone-releasing hormone (GH-RH), and bombesin/GRP and their receptors in the proliferation of various tumors are summarized, but the complete elucidation of all the mechanisms involved will require much additional work. Human tumors producing hypothalamic hormones are also discussed. Treatment of many cancers remains a major challenge, but new therapeutic modalities are being developed based on antagonists of GH-RH and bombesin, which inhibit growth factors or their receptors. Other approaches consist of the use of cytotoxic analogs of LH-RH, bombesin, and somatostatin, which can be targeted to receptors for these peptides in various cancers and their metastases. These new classes of peptide analogs should lead to a more effective treatment for various cancers.

Original languageEnglish
Pages (from-to)248-291
Number of pages44
JournalFrontiers in Neuroendocrinology
Volume22
Issue number4
DOIs
StatePublished - Nov 9 2001
Externally publishedYes

Fingerprint

Hypothalamic Neoplasms
Hypothalamic Hormones
Bombesin
Neoplasms
Somatostatin
Gonadotropin-Releasing Hormone
Growth Hormone-Releasing Hormone
Hormone Antagonists
Somatostatin Receptors
Peptides
Peptide Receptors
Intercellular Signaling Peptides and Proteins

Keywords

  • Agonists and antagonists of LH-RH
  • Bombesin antagonists
  • GH-RH antagonists
  • Somatostatin analogs
  • Targeted cytotoxic analogs
  • Tumor therapy

ASJC Scopus subject areas

  • Endocrine and Autonomic Systems
  • Endocrinology, Diabetes and Metabolism

Cite this

Schally, A. V., Comaru-Schally, A. M., Nagy, A., Kovacs, M., Szepeshazi, K., Plonowski, A., ... Halmos, G. (2001). Hypothalamic hormones and cancer. Frontiers in Neuroendocrinology, 22(4), 248-291. https://doi.org/10.1006/frne.2001.0217

Hypothalamic hormones and cancer. / Schally, Andrew V; Comaru-Schally, A. M.; Nagy, A.; Kovacs, M.; Szepeshazi, K.; Plonowski, A.; Varga, J. L.; Halmos, G.

In: Frontiers in Neuroendocrinology, Vol. 22, No. 4, 09.11.2001, p. 248-291.

Research output: Contribution to journalArticle

Schally, AV, Comaru-Schally, AM, Nagy, A, Kovacs, M, Szepeshazi, K, Plonowski, A, Varga, JL & Halmos, G 2001, 'Hypothalamic hormones and cancer', Frontiers in Neuroendocrinology, vol. 22, no. 4, pp. 248-291. https://doi.org/10.1006/frne.2001.0217
Schally AV, Comaru-Schally AM, Nagy A, Kovacs M, Szepeshazi K, Plonowski A et al. Hypothalamic hormones and cancer. Frontiers in Neuroendocrinology. 2001 Nov 9;22(4):248-291. https://doi.org/10.1006/frne.2001.0217
Schally, Andrew V ; Comaru-Schally, A. M. ; Nagy, A. ; Kovacs, M. ; Szepeshazi, K. ; Plonowski, A. ; Varga, J. L. ; Halmos, G. / Hypothalamic hormones and cancer. In: Frontiers in Neuroendocrinology. 2001 ; Vol. 22, No. 4. pp. 248-291.
@article{785189ba48e4443c8257b8b953c161d9,
title = "Hypothalamic hormones and cancer",
abstract = "The use of peptide analogs for the therapy of various cancers is reviewed. Inhibition of the pituitary - gonadal axis forms the basis for oncological applications of luteinizing hormone-releasing hormone (LH-RH) agonists and antagonists, but direct effects on tumors may also play a role. Analogs of somatostatin are likewise used for treatment of various tumors. Radiolabeled somatostatin analogs have been successfully applied for the localization of tumors expressing somatostatin receptors. Studies on the role of tumoral LH-RH, growth hormone-releasing hormone (GH-RH), and bombesin/GRP and their receptors in the proliferation of various tumors are summarized, but the complete elucidation of all the mechanisms involved will require much additional work. Human tumors producing hypothalamic hormones are also discussed. Treatment of many cancers remains a major challenge, but new therapeutic modalities are being developed based on antagonists of GH-RH and bombesin, which inhibit growth factors or their receptors. Other approaches consist of the use of cytotoxic analogs of LH-RH, bombesin, and somatostatin, which can be targeted to receptors for these peptides in various cancers and their metastases. These new classes of peptide analogs should lead to a more effective treatment for various cancers.",
keywords = "Agonists and antagonists of LH-RH, Bombesin antagonists, GH-RH antagonists, Somatostatin analogs, Targeted cytotoxic analogs, Tumor therapy",
author = "Schally, {Andrew V} and Comaru-Schally, {A. M.} and A. Nagy and M. Kovacs and K. Szepeshazi and A. Plonowski and Varga, {J. L.} and G. Halmos",
year = "2001",
month = "11",
day = "9",
doi = "10.1006/frne.2001.0217",
language = "English",
volume = "22",
pages = "248--291",
journal = "Frontiers in Neuroendocrinology",
issn = "0091-3022",
publisher = "Academic Press Inc.",
number = "4",

}

TY - JOUR

T1 - Hypothalamic hormones and cancer

AU - Schally, Andrew V

AU - Comaru-Schally, A. M.

AU - Nagy, A.

AU - Kovacs, M.

AU - Szepeshazi, K.

AU - Plonowski, A.

AU - Varga, J. L.

AU - Halmos, G.

PY - 2001/11/9

Y1 - 2001/11/9

N2 - The use of peptide analogs for the therapy of various cancers is reviewed. Inhibition of the pituitary - gonadal axis forms the basis for oncological applications of luteinizing hormone-releasing hormone (LH-RH) agonists and antagonists, but direct effects on tumors may also play a role. Analogs of somatostatin are likewise used for treatment of various tumors. Radiolabeled somatostatin analogs have been successfully applied for the localization of tumors expressing somatostatin receptors. Studies on the role of tumoral LH-RH, growth hormone-releasing hormone (GH-RH), and bombesin/GRP and their receptors in the proliferation of various tumors are summarized, but the complete elucidation of all the mechanisms involved will require much additional work. Human tumors producing hypothalamic hormones are also discussed. Treatment of many cancers remains a major challenge, but new therapeutic modalities are being developed based on antagonists of GH-RH and bombesin, which inhibit growth factors or their receptors. Other approaches consist of the use of cytotoxic analogs of LH-RH, bombesin, and somatostatin, which can be targeted to receptors for these peptides in various cancers and their metastases. These new classes of peptide analogs should lead to a more effective treatment for various cancers.

AB - The use of peptide analogs for the therapy of various cancers is reviewed. Inhibition of the pituitary - gonadal axis forms the basis for oncological applications of luteinizing hormone-releasing hormone (LH-RH) agonists and antagonists, but direct effects on tumors may also play a role. Analogs of somatostatin are likewise used for treatment of various tumors. Radiolabeled somatostatin analogs have been successfully applied for the localization of tumors expressing somatostatin receptors. Studies on the role of tumoral LH-RH, growth hormone-releasing hormone (GH-RH), and bombesin/GRP and their receptors in the proliferation of various tumors are summarized, but the complete elucidation of all the mechanisms involved will require much additional work. Human tumors producing hypothalamic hormones are also discussed. Treatment of many cancers remains a major challenge, but new therapeutic modalities are being developed based on antagonists of GH-RH and bombesin, which inhibit growth factors or their receptors. Other approaches consist of the use of cytotoxic analogs of LH-RH, bombesin, and somatostatin, which can be targeted to receptors for these peptides in various cancers and their metastases. These new classes of peptide analogs should lead to a more effective treatment for various cancers.

KW - Agonists and antagonists of LH-RH

KW - Bombesin antagonists

KW - GH-RH antagonists

KW - Somatostatin analogs

KW - Targeted cytotoxic analogs

KW - Tumor therapy

UR - http://www.scopus.com/inward/record.url?scp=0034771199&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034771199&partnerID=8YFLogxK

U2 - 10.1006/frne.2001.0217

DO - 10.1006/frne.2001.0217

M3 - Article

VL - 22

SP - 248

EP - 291

JO - Frontiers in Neuroendocrinology

JF - Frontiers in Neuroendocrinology

SN - 0091-3022

IS - 4

ER -